Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
18 stopped studies mapped to Prolymphocytic Leukemia and descendants · 67% state a reason
Over the 18 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory… | Phase 1 | terminated | Aug 26, 2020 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT01629511 | Allogeneic Stem Cell Transplant for CLL | Phase 1 / Phase 2 | terminated | Jun 27, 2012 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT02662296 | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic… | Phase 2 | withdrawn | Jan 25, 2016 | Fred Hutchinson Cancer Center | Low enrollment | Enrollment / accrual |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT02285244 | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | withdrawn | Nov 6, 2014 | James Blachly | Decision made by the Principal Investigator | Investigator |
| NCT00098371 | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | CTEP Initiated Action. | Other (stated, no rule matched) |
| NCT00281931 | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic… | Phase 2 | terminated | Jan 25, 2006 | German CLL Study Group | not stated | Not stated |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell… | Phase 1 | terminated | Feb 26, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic… | Phase 1 | terminated | May 19, 2010 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | Phase 2 | terminated | Oct 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00612612 | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated… | Phase 1 | terminated | Feb 11, 2008 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00098488 | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients… | Phase 1 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00005786 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | N/A | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem… | N/A | withdrawn | Mar 20, 2012 | Roswell Park Cancer Institute | device not available | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 21, 2026source: clinicaltrials